A study demonstrating users' preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE

CTCAE REQUITE lung cancer patient reported outcome quality of life symptoms

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2024
Historique:
received: 27 10 2023
accepted: 27 03 2024
medline: 25 4 2024
pubmed: 25 4 2024
entrez: 25 4 2024
Statut: epublish

Résumé

The use of patient-reported outcomes (PROs) has been shown to enhance the accuracy of symptom collection and improve overall survival and quality of life. This is the first study comparing concordance and patient preference for two PRO tools: Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE Patients with lung cancer were recruited to the study while attending outpatient clinics at a tertiary cancer centre. Clinician-reported outcomes were generated through initial patient assessment with CTCAE v4.03. Participants then completed the PRO-CTCAE Out of 74 patients approached, 65 provided written informed consent to participate in the study. 63 (96.9%) patients completed both PRO-CTCAE The adapted-REQUITE questionnaire has shown a superior correlation to clinician-reported outcomes and higher patient preference than the PRO-CTCAE

Identifiants

pubmed: 38660130
doi: 10.3389/fonc.2024.1328871
pmc: PMC11039780
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1328871

Informations de copyright

Copyright © 2024 Jordan, Nuamek, Fornacon-Wood, Califano, Coote, Harris, Mistry, Taylor, Woolf and Faivre-Finn.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Thomas Jordan (T)

Division of Cancer Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom.
The Christie NHS Foundation Trust, Manchester, United Kingdom.
Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Wigan, United Kingdom.

Thitikorn Nuamek (T)

The Christie NHS Foundation Trust, Manchester, United Kingdom.

Isabella Fornacon-Wood (I)

Division of Cancer Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom.
The Christie NHS Foundation Trust, Manchester, United Kingdom.

Raffaele Califano (R)

Division of Cancer Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom.
The Christie NHS Foundation Trust, Manchester, United Kingdom.

Joanna Coote (J)

The Christie NHS Foundation Trust, Manchester, United Kingdom.

Margaret Harris (M)

The Christie NHS Foundation Trust, Manchester, United Kingdom.

Hitesh Mistry (H)

Division of Cancer Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom.

Paul Taylor (P)

The Christie NHS Foundation Trust, Manchester, United Kingdom.

David Woolf (D)

The Christie NHS Foundation Trust, Manchester, United Kingdom.

Corinne Faivre-Finn (C)

Division of Cancer Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom.
The Christie NHS Foundation Trust, Manchester, United Kingdom.

Classifications MeSH